NCT04398147View on ClinicalTrials.gov

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

696

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

December 20, 2021

Study Completion Date

December 30, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular administration

BIOLOGICAL

Placebo

Intramuscular administration

Trial Locations (1)

Unknown

Canadian Center for Vaccinology, Halifax

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biotechnology

OTHER

collaborator

Canadian Center for Vaccinology

OTHER

lead

CanSino Biologics Inc.

INDUSTRY

NCT04398147 - Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada | Biotech Hunter | Biotech Hunter